Precision Medicine Strategies: Designing Individual
Transcription
Precision Medicine Strategies: Designing Individual
Chicago Chapter Precision Medicine Strategies: Designing Individual-Specific Care May 29, 2014 @ 1871, Chicago IL Event Sponsors Chicago Chapter In the past decade, the emergence of personalized/precision medicine has ushered in a groundbreaking era in healthcare, challenging current delivery models and practices. Precision medicine has the ability to provide dramatically improved diagnosis, prognosis, and patient treatment processes. This new model of medicine and healthcare has been nurtured by emerging cost-effective and cutting-edge science in genome sequencing, incorporating molecular information into patient records with the aim to deliver: "The right treatment … …for the right person… …at the right time." AGENDA PANELISTS May 29, 2014 @ 1871, Chicago IL 5:15 - 6:10 pm Registration / Networking Reception Bahija Jallal, Ph.D. 6:10 - 7:40 pm Introduction – Ikbel Achour, Ph.D. Seema Kumbhat, M.D. Director of Precision Health University of Arizona EL Chicago Council on Global Affairs WIB-Chicago Funding Chair Welcome Remarks – Christina Fleming, Ph.D. President and CSO, Pharma Start Panel Discussion & Q/A Executive Vice President of AstraZeneca, Head of MedImmune Global Medical Director-Biologics, Hospira Olufunmilayo Olopade, M.D., FACP, OON Professor of Medicine and Human Genetics, Associate Dean of Global Health, and Director of the Center for Clinical Cancer Genetics, University of Chicago Concluding Remarks – Jamie Dananberg, M.D. Pia Gargiulo, Ph.D. Executive Vice President, Head, Therapeutic Area Group, Takeda Pharmaceuticals International, Inc. Moderator Chris Meda, M.S. Managing Director, PGx Consulting Chief Business Officer, incellDx 7:40 - 8:15 pm Dessert / Networking Reception Event Sponsors Bahija Jallal,Ph.D. Executive Vice President of AstraZeneca, Head of MedImmune a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK. Dr. Jallal has guided, since 2006, the MedImmune R&D organization through unprecedented growth and expansion of its biologics pipeline from 40 drugs to more than 120 today. She inspires creativity, out-of-the-box thinking and a dedication to scientific excellence to the more than 2,500 employees at MedImmune. Dr Jallal serves as a member of the Board of Directors for the Association of Women in Science and an advisory member of the Healthcare Business Women’s Association. Dr. Jallal has authored over 70 peer-reviewed publications and has over 15 patents." Olufunmilayo Olopade, M.D., FACP, OON Professor of Medicine and Human Genetics, Associate Dean of Global Health, and Director, Center for Clinical Cancer Genetics, University of Chicago. A global leader in cancer genetics, Dr. Olopade seeks to identify those at risk for hereditary breast and ovarian cancer earlier in life, intervene aggressively to reduce risk and preempt disease development to effectively control cancer. She studies familial forms of cancers, molecular mechanisms of tumor progression in high-risk individuals as well as genetic and non-genetic factors contributing to tumor progression in diverse populations. Her current laboratory research is focused on using whole genome technologies and bioinformatics to develop innovative approaches to accelerate progress in cancer research and reduce disparities in health outcomes. Seema Kumbhat, M.D. Pia Gargiulo, Ph.D. Global Medical Director-Biologics, Hospira Managing Director, PGx Consulting Dr. Kumbhat has more than 18 years of experience in healthcare. At Merck, she launched several new drugs for osteoporosis, hypertension, and hypercholesterolemia in South Florida, growing this market to #1 in the nation. Currently at Hospira, she has developed new tools and programs for early detection of complex clinical conditions, drug-device combination solutions, and currently serves as Global Medical Director, Biologics, where she is responsible for bringing Hospira’s biosimilar pipeline to approval, globally. Dr. Kumbhat’s honors include several clinical publications and speaking engagements. Recently, she was elected to the Emerging Leaders Program, Chicago Council on Global Affairs, class of 2013. Dr. Gargiulo has lead teams in the development and delivery of companion programs focusing on the utility and uptake of commercialization models for both the pharmaceutical and diagnostic sectors. Dr Gargiulo has worked on 8 PMA Submissions resulting in three pivotal Companion Drug-Diagnostic Offerings to Breast, Colorectal, and Lung Cancer Patients. She joined Precision Health Holdings in 2012 as Managing Director of Companion Diagnostic Solutions. Prior to this, she was Vice President at Qiagen, overseeing the Companion Diagnostic Partnership Team, which was responsible for the delivery over 12 companion diagnostic programs. She is a regional member of the American Cancer Society, I-Bio and World Business Chicago and was recently appointed to the Governor’s Commission on Women’s Health. Chris Meda, M.S. Christina Fleming, Ph.D. Chief Business Officer, IncellDx Meda has 30 years of leadership in the global diagnostic and pharmaceutical Industries. Her management responsibilities have included the creation of worldwide strategic business direction and plans, operations and commercialization of more than 30 products for various disease areas at Hoffman-LaRoche, Schering AG pharmaceuticals, Bio-Rad Laboratories, Diagnostics Products Corporation (now Siemens), Meridian Diagnostics. Currently, Meda is CBO at IncellDx; Chair, of Women in BIO-San Francisco Chapter; and, a Board Director for Claremont BioSolutions, a company providing laboratories with diagnostics and devices for molecular diagnostics and bioscience research. Jamie Dananberg, M.D. Executive Vice President, Head, Therapeutic Area Group, Takeda Pharmaceuticals International, Inc. Dr. Dananberg has served in a wide range of leadership positions in healthcare. Until July 2012, he was Vice President, Translational Medicine and Tailored Therapeutics leading global clinical pharmacology, Pharmacogenomics, Diagnostic and Experimental Medicine (Clinical Pathology), Laboratory for Experimental Medicine, and Translational Imaging. Most recently, he serves as Head of Therapeutic Areas at Takeda. He remains active in the Indiana Clinical and Translational Science Institute. He participates on a number of external groups focused on personalized medicine and he has also been involved in a number of innovation-centered efforts within the biomedical research community. President and CSO, Pharma Start As the founder of Pharma Start, Dr. Fleming provides the company’s strategic direction by leveraging her 20+ years of biopharmaceutical and CRO industry experience. Dr. Fleming’s experience includes building, managing and leading Clinical Development, Medical Writing, and Pharmacovigilance Divisions at Searle, TAP, Neopharm Inc., and Baxter Healthcare as well as developing the outsourcing/CRO consulting services at several CROs. This experience led her to create and develop Pharma Start into a highly successful and unique outsourcing organization. Dr. Fleming earned her Bachelor of Science (BS) in Biology at Saint Mary's College and her Doctor of Philosophy (PhD) in Pharmacology from the University of Illinois at Chicago. " " Medicine & Healthcare moving forward ‘’One drug fit all’’ Stratified – Personalized – Precision Medicine Towards smaller population to one individual/patient design The use of molecular data such as genomics, epigenomics, exposure, and other data define individual disease profile with the potential to provide individualized and precise treatment The use of a companion diagnostic to predict in advance which patients are most likely to benefit from a particular therapy Considering current and emerging examples in which therapies are matched with specific patient population characteristics using clinical biomarkers or genomics profiling APPROACHES Drug Development "Rx" Value of Precision Medicine DISCOVERY" DEVELOPMENT" Iden9fica9on"of" Mechanisms"" Linked"to"Human" Disease" Improved"Therapeu9c" Index"in"Selected" Pa9ent"" Subpopula9on" REGULATORY" Superior"Safety"&"Efficacy" Profile"in"PreTdetermined" Pa9ents" CLINICAL"PRACTICE" Op9miza9on" Of"Pa9ent"Care" Applica9on"of"Knowledge"From"Extensive"Pa9ent"Experience"–"" to"every"stage,"within"a"dynamic"R&D"environment"" Companion Diagnostics vs. Complementary Diagnostics Both are molecular assays that measure levels of proteins, gene expression, or presence of specific mutations to assess a patient's risk factor for a number of conditions to provide a specific therapy at the one individual/patient level. COMPLEMENTARY Diagnostics Tests that are being developed in parallel with the drug that is currently in development (FDA term) COMPANION Diagnostics Tests that have been developed independently / after a drug has come to market Outcomes Increased Improved likelihood of patient response to therapy patient management More efficient clinical trial design Reduced societal costs Identification of other patients likely to respond owing to genetic alterations in target pathway APPROACHES Companion Diagnostic Development "CDx" Prototype"Assay" Phase"I" Locked"Assay" Phase"II"A" Feasibility Phase Assess Biomarker POC" Final"Assay" Phase"II"B" Phase"III" Development Phase Establish Performance IVD"PreTSubmission" Mee9ng" Design" "Lock" Validation Phase Verify Performance IDE"" Submission" NDA" Validate Design PMA"" PMA"" Design" Transfer" PreTSubmission" Submission" Mee9ng" Source:(2014,(FDA(Companion(Diagnos9cs(Website( Major Trends in Personalized / Precision Medicine POLITICAL – Effectiveness to Cost-effectiveness Worldwide acceptance that healthcare $$ are finite Increased emphasis on economic efficiency; comparative effectiveness Increasing CDx from BioPharma" SCIENTIFIC – Targeted Therapies Advances in understanding of disease processes leading targeted drugs – precision on specific molecular targets Increasing demand for CDx tools to classify disease sub-types and predict those likely to respond to therapy REGULATORY – Passive to Active Regulatory authorities realized benefits of CDx to patients. FDA and EMA encouraging Rx companies to explore the use of CDx during drug development CDx-Rx combination will become a mandatory path of NDA/BLA submission and product labeling Benefits of Personalized Healthcare PATIENTS PHYSICIANS Increased effectiveness of therapies Increased safety in treatment decisions PAYERS Better outcomes for lower costs Rx COMPANIES Regulatory approval and competitive advantage CDx COMPANIES New market opportunities Seven Critical Issues for Commercial Readiness CLINICAL Sufficient data to demonstrate the clinical utility TECHNICAL Assays need to be reliable, robust and compatible with lab operations REGULATORY Approval needed for the drug, the diagnostic and (in US) the instrument AVAILABILITY Needs to match the global distribution of the drug if there is a pharma partner REIMBURSEMENT Early strategy for value-based $ for CDx IP Technology and genetic licenses in place COMMERCIAL Different models needed depending on level of drug company involvement is delighted in your interest and participation in events and initiatives supporting Chicago’s and Illinois’ life sciences community. Our local footprint provides a home to individuals from world-class research institutions, multinational life sciences companies, non-profit organizations and entrepreneurial companies, as well as a growing number of investors and professional service providers committed to the life science industry. The State of Illinois is a leader in biotech and pharma, ranking as one of the top ten states in terms of both number of businesses and R&D expenditures. This foundation provides fertile ground upon which to build our WIB chapter, and we invite new members to join us in this venture. Thank&you.&& Become a MEMBER Become a SPONSOR Chicago Chapter - Our Team ! Katherine Neville – Chapter Chair Larisa Lacis – Chapter Vice Chair ! Dimitra Georganopolou – President Elect Funding Committee ! Ikbel Achour – Chair ! Carolyn Hollands – Vice Chair Jessica Hilliard ! Bich Duong Emily Miao Shyama Majumdar Programming Committee ! Michelle Kouba – Chair Carolyn Brougham – Vice Chair ! Alis Gjeci Elese Hanson ! Heather Kissling Sherri Oslick Emily Miao Alyssa Master Membership Committee ! Lynn Janulis – Chair Communication Committee ! Heather Kissling – Chair ! Lynn Janulis – Vice Chair Julie Langdon – Vice Chair ! Tina Rogers Erica Watson Tanya Yankelvich Young Women In Bio Committee ! Sharon Sintich – Chair May 29th event ! Organizers ! Volunteers JOIN&US&@&& WIB at 2014 BIO Convention, San Diego WIB Chicago Summer Events VISIT"US"at"the"Exhibit"Hall"Booth"#2403."" June 23, 2014 – Welcome Celebration June 18, 2014 – Symphony in the Park 4:00 p.m. at Hilton San Diego Bayfront, Sapphire Terrace. Honored guest Annalisa Jenkins M.D., a leading figure in the biopharmaceutical industry. 4:45 p.m. at Millennium Park July 17, 2014 – Book Club 6 p.m. at Katten, Muchin and Rosenman Book: “The Confidence Code” by June 24 and 25, 2014 – Meet up 2:00 p.m. and 3:00 p.m. at Booth #255. WIB-Southern California Area Professionals and Executives in the Life Science Industry (June 24) Speed Networking for Existing and Prospective WIB Members (June 25) [email protected]" h]p://www.womeninbio.org/wibTchapters/chicago" Katty Kay & Claire Shipman August 14, 2014 – Metro Mix and Mingle Networking Event 5:30 p.m. at two locations: Northshore – Cooper's Hawk Winery Downtown – The Kerryman REGISTER TOPICS&OF&THE&DAY& EVENT SPONSORS !& “The"science"has"never"been"be]er’’" " !& Companion"vs."Complementary"Diagnos9cs" " Diagnos9cs"Key"Benefits:"Pa9ents/Individuals,"" !& Physicians,"Healthcare"System,"Pharmaceu9cal"" and"Diagnos9c"Companies""" " !& “Clashing"Interests”"–"What"Are"They?" !& How"Do"We"Accelerate"To"Market?" " " !& Economics:"Reimbursement,"Affordable,"" Emerging"Markets" @WomenInBio" #precisionmed" #WIBevents""